Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoVaccine Technologies, a vaccine development company, has signed a three-year research agreement with Defence R&D Canada or DRDC.
Subscribe to our email newsletter
The research collaboration involves the preclinical application of ImmunoVaccine Technologies’s (IVT’s) DepoVax vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.
Marc Mansour, vice president of R&D at IVT, said: “Because our DepoVax formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine.”